Relapsed or Refractory Diffuse Large B-Cell Lymphoma / RR DLBCL
Phase 1b (Results)
Amp Volatility Score
Catalyst Info & Data Links
TITLE: Lenzilumab for Relapsed or Refractory Large B-Cell Lymphoma - Phase 1b Results
ClinicalTrial.gov (NCT04314843): Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma (ZUMA-19)
WHAT IS THE NEXT CATALYST EVENT?
1. Phase Ib results
2. Phase II interim analysis
3. Six-month efficacy data
See slide 8 of the corporate slide deck at this LINK
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
1. December 2020 (Q4 2020)
2. H1 2021
3. H2 2021
07-2020: Corporate Presentation (slides 5, 17-18)
2018: Graft-versus-host disease, but not graft-versus-leukemia immunity, is mediated by GM-CSF–licensed myeloid cells. Science translational medicine, 10(469).
2019: Donor T-cell–derived GM-CSF drives alloantigen presentation by dendritic cells in the gastrointestinal tract. Blood advances, 3(19), 2859-2865.
2019: GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood, The Journal of the American Society of Hematology, 133(7), 697-709.
2020: A new role for an old cytokine: GM-CSF amplifies GVHD. Blood, 135(8), 520-521.
MECHANISM OF ACTION / RATIONALE
A recombinant monoclonal antibody against the cytokine granulocyte macrophage colony-stimulating factor (GM-CSF), with potential immunomodulating activity. Upon administration, lenzilumab binds to and neutralizes GM-CSF. This prevents GM-CSF binding to the GM-CSF receptor, which is a heterodimeric protein expressed on myeloid progenitor cells, and prevents GM-CSF-mediated signaling. This may induce apoptosis in and inhibit proliferation of cancer cells that overproduce GM-CSF. GM-CSF plays a key role in the differentiation and proliferation of monocytes, macrophages and granulocytes; elevated levels of GM-CSF are associated with certain autoimmune diseases, inflammatory diseases, and cancers. (Learn more - Cancer.gov)
Updated by HC
#HGEN, #Lenzilumab, #granulocyte_macrophage_colony-stimulating_factor, #GM-CSF, #ZUMA-19, #B-Cell_Lymphoma, #DLBCL
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post